Internal Medicine, Infectious Disease · Stanford, CA
NPI
1205949070
Since 2006
Specialty
Internal Medicine, Infectious Disease
Code 207RI0200X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
300 Pasteur Dr
Stanford, CA, 94305
Phone (650) 723-4000
Groups this clinician bills Medicare through
Medicare paid, 2024
$59K
501 services
Medicare patients, 2024
209
Average age 70
Drug cost, 2024
$3.0M
3,601 prescriptions
Company payments, 2025
$41.66
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Philip M Grant was code 99233 (hospital e&m - subsequent), 203 times for 88 patients. In total Philip M Grant billed 501 services in 15 codes, and Medicare paid $59K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-04-26.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99233 Hospital E&M - Subsequent | Facility | 203 | 88 | $105.94 | $22K |
| 99215 Office E&M - Established | Facility | 129 | 53 | $108.38 | $14K |
| 99223 Hospital E&M - Initial | Facility | 96 | 93 | $153.79 | $15K |
| 99215 Office E&M - Established | Office | 41 | 19 | $148.06 | $6,070 |
By year: 2022 $31K for 276 services; 2023 $53K for 441 services; 2024 $59K for 501 services.
Medicare prescription drug claims, 2024
In 2024, the drug Philip M Grant prescribed most often to Medicare patients was Biktarvy (Bictegrav/Emtricit/Tenofov Ala), with 262 prescriptions and refills. In total Philip M Grant wrote 3,601 Medicare prescriptions that cost $3.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | 262 | 271 | 32 | $1.1M |
| Gabapentin Generic | 118 | 151 | 20 | $2,174 |
| Atorvastatin Calcium Generic | 114 | 246 | 28 | $881 |
| Juluca Dolutegravir/Rilpivirine | 93 | 93 | Under 11 | $330K |
| Descovy Emtricitabine/Tenofov Alafenam | 89 | 107 | 16 | $235K |
| Oxycodone Hcl Generic | 87 | 87 | 12 | $2,223 |
| Tivicay Dolutegravir Sodium | 83 | 91 | 13 | $226K |
| Lorazepam Generic | 61 | 61 | Under 11 | $274 |
| Albuterol Sulfate Hfa Albuterol Sulfate | 58 | 66 | 12 | $2,582 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 54 | 54 | Under 11 | $1,382 |
| Odefsey Emtricitab/Rilpiviri/Tenof Ala | 52 | 52 | Under 11 | $183K |
| Amlodipine Besylate Generic | 50 | 90 | 12 | $303 |
| Hydrochlorothiazide Generic | 50 | 110 | 13 | $128 |
| Genvoya Elviteg/Cob/Emtri/Tenof Alafen | 49 | 49 | Under 11 | $187K |
| Dovato Dolutegravir Sodium/Lamivudine | 47 | 49 | Under 11 | $153K |
Brand drugs: - claims; generic drugs: 2,484 claims; opioid claims: 318.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Philip M Grant $41.66 ($41.66 in general payments such as food, travel and fees) from 1 company. The largest payer was Gilead Sciences, Inc. with $41.66.
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. GILD | 2 | $41.66 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.